Anti-PD-1 and anti-PD-L1 antibodies have demonstrated effectiveness in various cancer treatments, including advanced melanoma and non-small cell lung cancer, yet their application in BC has been less effective 25-27. This evidence concerns the gene PDCD1 and cancer.